Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744187 | 0.86 | GFER (0.47) | TP53MAPTLMNAKDM4EUSP2 | |
| SCHEMBL8345252 | 0.70 | SMN1; SMN2 (0.52) | MAPTLMNAL3MBTL1NPC1ALDH1A1 | |
| SCHEMBL5745194 | 0.68 | MCL1 (0.50) | ALDH1A1 | |
| SCHEMBL16491948 | 0.66 | PPARG (0.59) | TP53MAPTKDM4ETDP1ALDH1A1 | |
| SCHEMBL5334332 | 0.66 | MMP9 (0.59) | TP53MAPTLMNAKDM4ETDP1 | |
| SCHEMBL16689961 | 0.65 | KMT2A (0.67) | MAPTLMNAKDM4ETDP1NPC1 | |
| SCHEMBL6750671 | 0.65 | THRB (0.45) | TP53MAPTKDM4EALDH1A1ADORA2A | |
| SCHEMBL5746254 | 0.64 | PPARG (0.45) | ALDH1A1 | |
| SCHEMBL1278792 | 0.64 | TAS2R14 (0.78) | MAPTLMNAALDH1A1 | |
| SCHEMBL16689955 | 0.64 | SMPD1 (0.59) | MAPTTDP1NPC1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043984-A1 | 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014389-A1 | 3,4-DIHYDROQUINOLIN-2-ONE, 5,6-FUSED OXAZIN-3-ONE, AND 5,6-FUSED THIAZIN-3-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043984-A1 | 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors | MMP13, MMP9, MMP3 | TP53 3965/4885MAPT 1797/4885LMNA 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.